Changing DermatologyThrough Fluorescent Light Energy

Commercial focus on partnerships with

private dermatological clinics

offering THERAPEUTIC as well

as AESTHETICsolutions

The WHAT: Kleresca® at a glance

Established March 2017 as a

spin-out of LEO PHARMA A/S, Denmark and KLOX

TECHNOLOGIES, Canada

Developing markets in

10 COUNTRIES around the world

LEO PHARMA A/S and KLOX

TECHNOLOGIES are primary

shareholders

Headquartered in DUBLIN, IRELAND

with a branch office in DENMARK, the

company is currently employing app. 50

dedicated staff

The company is registered as

FB DERMATOLOGY and KLERESCA®

FOUR PRODUCTS Presently for acne, skin rejuvenation,

rosacea and pre-post

2

At Kleresca®, we aspire to change the fundamentals of dermatology. Our innovative biophotonic technology is unique in our field and allows us to create a new gold standard within the industry for the benefit of patients worldwide.

We strive to change people’s lives a little bit every day. Essentially by helping people feel good about their skin.

The WHY: Or the reason we go to work

3

● Klerescians come in many shapes and sizes but common to all are the entrepreneurial spirit, the passion for our technology and the love of our tribe.

● Klerescians are empowered doers who take responsibility and execute without fear of failure even outside of our comfort zones. We support each other across borders, languages and cultures.

● Klerescians are focused yet agile and are more concerned about value creation than job functions. We love the freedom to do what it takes, not only what is required.

● Klerescians are motivated by the possibility of changing people’s lives. We are touched by personal stories and aim to make a difference every day.

The WHO: The Global Klerescian

4

DR. MICHAEL ENGELBRECHT NIELSEN

Director Science & Clinical Affairs

LARS BAK-CHRISTENSENDirector Expansion, Quality & RA

LIAM MURPHYFinance Director

LACHLAN MOLONYDirector Market Development

HILDE VOIE-ANDERSENDirector Marketing & PR

The WHO: Chief Klerescians

MIKKEL SCHOEDTGeneral Manager

Highly experienced within the medical sector, Mr. Schoedt has worked as a consultant for medical/high tech companies and has led turn-arounds in Coloplast and LEO Pharma. Experience in building businesses in Denmark and the US within cardiology, neurology, and venerology. A medical biochemist by education, Mr. Schoedt also has research experience from Novo Nordisk. Being responsible for the overall management of the company, Mr. Schoedt is based in Denmark.

International profile with a long track record within the medical device and pharmaceutical industries. More than 15 years of experience with product and marketing management across markets, languages and cultures in companies such as Invacare, Unomedical, ConvaTec and LEO Pharma. Holds an Executive MBA from Griffith University (Australia) and a Bachelor of Nursing from The University of Agder (Norway). Mrs. Voie-Andersen is based in Denmark.

Sales leader and market developer with a long track record from the medical device and pharmaceutical sectors. Mr. Molony has built, managed and developed national and international sales teams to consistently deliver achievement of corporate goals. Holding a degree in biotechnology, he has gained diverse experience working with Boehringer Ingelheim, Stryker and LEO Pharma before joining Kleresca® in 2015. Mr. Molony works out of the Netherlands.

Experienced head of finance, ACMA qualified, with significant finance, operation and fund-raising experience from US multinationals such as Benchmark Electronics, Stratus Computers, Hewlett Packard and venture capital financed software company Shenick. Mr. Murphy is responsible for Kleresca®’s overall finances and is based in Dublin.

Having worked in market development and expansion for more than 30 years, Mr. Bak-Christensen is a highly experienced executive with merits from the medical device and pharmaceutical industries. With a degree in foreign trade, international management and business, he has built extensive knowledge and insight from executive positions in international companies like Decumed, Cardinal Health, Contura, Ferrosan and Radiometer. Mr. Bak-Christensen is based in Denmark.

Associate professor from the Danish Technical University, DTU and Copenhagen University with a collaborative PhD from Tokyo University, Japan. With a key focus on cellular biology, immunology and applied science collaborations, Mr. Nielsen is responsible for developing the technological platform of Kleresca® through research and studies. Mr. Nielsen is based in Denmark and Italy.

5

The WHAT: Our offer

The gel is applied to the patient’s skin and illuminated under the lamp for nine minutes

1The chromophores in the gel convert the blue light from the lamp into fluorescent light energy

2The fluorescent light energy penetrates the skin triggering documented healing responses

3

4 products based on fluorescent light energy (FLE) This is what happens

Multi LED lamp with optimised

wavelengths

Optimised gels for each

indication

Fluorescent light energy

for all treatments

6

Dermatologists

Aesthetic Clinics

Plastic Surgeons

The WHERE: Our Market

● At present Kleresca® offers in-clinic treatments only

● We work exclusively with high-end private clinics and clinic chains

● Strengthened focus on clinic chains and commercial partnerships going forward into 2019 to scale business

● Key markets are Europe and Australia that we are currently consolidating

● In selected markets we are piloting efforts to obtain public reimbursement

● We are looking to enter the US in 2020

7

IPL/laser treatments

Systemic antibiotics

Benzoyl peroxide

Fillers incl. Botox

Skin peelings

Isotretinoin

Stimulates the skin’s

own repair mechanisms

Destresses and

revitalises the skin

Normalises the

biological processes

Stand alone treatment or in

combination with more

invasive procedures +

+

+

+

+

+

The WHERE: All round

8

1. Market research by PRIME and byReportsnReports, Aug 20162. Market research by PR Newswire and PMR Study, May 2017

The WHERE: Market outlook

● MEDICAL AESTHETICS MARKET1

● Estimated market size 50B $

● Estimated CAGR 4,5-6%

● ACNE TREATMENT MARKET2

● Estimated market size 5B $

● Estimated CAGR 4,6%

● ROSACEA TREATMENT MARKET

● Estimated market size 3B $

● Estimated CAGR 6%

Valu

e

Unmet Needs

Aesthetics50B $

Acne5B$

Rosacea3B$

9

Surgery

Invasive techniques

Cosmetics

Instant results

Augment appearance

Natural look

Enhanced emphasis on safety and experience

• Patients are no longer looking to alter their appearance dramatically

• “Look your best” seems to be prevailing, calling for gentle and comfortable treatments with high efficacy and safety serving new generations of patients who demand high standards

• Kleresca® is meeting an unmet need with a technology that:

• Facilitates healthier, natural looking skin • Improves overall skin quality• Stimulates the skin’s own repair mechanisms• Is gentle • Offers limited to no downtime• Has documented high safety and efficacy

The TRENDS

10

Milestones looking back

11

Milestones looking forward

12

The RESEARCH: Q4 2018 going forward

Current Clinical and Scientific Development Q4 2018

Currently four clinics are conducting case studies in relation to inflammatory skin diseases

In collaboration with Copenhagen University, a full time Kleresca® post doc researches the biology of fluorescent light energy as a novel therapeutic modality

We are currently conducting research in relation to gel formulations in collaboration with the Danish Technical University (DTU), Department of Photonics

Currently conducting EU subsidised project researching optimisation of our light source in collaboration with DTU and the University of Modena, Italy

Currently rolling out post market multiclinic study for rosacea involving DK, DE, ES, IT and FR

Ongoing development of clinical documentation / measuring tool in relation to aesthetic improvement from our treatment in collaboration with Italian partner clinic

Ongoing collaboration with all treating clinics in relation to optimization of Kleresca® treatments and regimens

13

A solid exposure is required to gain a footing in the high end aesthetic skin care industry.

While current exposure provides a good basis, further investment is needed to increase public reach.

The MEDIA: Gaining a footing online

Overall increase in editorial hits of 7K% compared to same time last year*

+400 editorial hits

+1,200 SoMe hits

Potential Reach 96.4M(approximate number of article views)

*change compared to Jul 1st 2017 - Sep 30th 2017

MailOnline, Australia Woman.at, Austria

Vogue, Italy Today Tonight TV show, Australia

Marie Claire, Spain

Mabelle, Germany

14

THE TECHNOLOGYPhotobiomodulation and fluorescent light energy

About photobiomodulation (PBM)

● Light moves in waves, measured in nanometres (nm)

● Visible light is just a very small part of the whole spectrum

● Visible light is defined in the range of 400 – 700 nm

● Depending on its wavelength, light penetrates differently into the skin, gaining access to a variable selection of biological elements

16

All the graphics belong to Kleresca® / FB Dermatology Limited. FB Dermatology Limited © 2018

About photobiomodulation (PBM)

17

KLERESCA® ACNE TREATMENTNo more hiding

WHAT IS ACNE?

PERFECT MARKET FITAcne

● Kleresca® Acne Treatment can be used as a stand alone treatment or in addition to traditional therapies

● As the treatment is gentle with high safety and efficacy, it is an attractive alternative to patients who are less inclined to accept side effects and downtime

● The treatment regime is adaptive in relation to the severity of the condition. Number of treatments is subject to the evaluation of the treating clinician

20

TREATMENT BENEFITSAcne

A NON-INVASIVE MULTI-ACTION TREATMENT● Kills bacteria responsible for acne (P. acnes)

● Reduces inflammation

● Encourages collagen build-up stimulating acne scars repair

NO MORE TRADE-OFFS IN SAFETY AND EFFICACY● Non-abrasive, non-invasive treatment with high efficacy and safety

● Pleasant and comfortable experience with little to no downtime

● Long-lasting effects. The skin continues to improve months after the

treatment has finished

● Solid clinical trials with positive outcomes for patients

21

TREATMENT EFFICACYAcne

*The treating physician gave the patient a booster treatment in week 33. Individual results may vary.

WEEKLY IMPROVEMENT

22

KLERESCA® SKIN REJUVENATION (SKR)Skin rejuvenation reimagined

WHAT IS SKIN AGEING?

● Loss of density and volume

● Noticeable wrinkles in the skin

● Skin becomes drier and loses radiance

● The overall collagen content of the skin’s surface is known to decrease by approximately 1% each year from the time you are about 20 years old

● Different factors contribute to ageing such as the passing of time and exposure to external elements (wind, sun, pollution, etc.)15,17

NB: Ageing is not a disease; it is an inevitable process of human evolvement and it should be perceived that way.

24

PERFECT MARKET FITSkin Rejuvenation

● Kleresca® Skin Rejuvenation is unique in its mode of action and fits well with markets trends

● It can be used as a stand alone treatment or in addition to traditional therapies

● It challenges the misconception of ”no pain, no gain” by being gentle with high safety and efficacy

● It is an attractive alternative to people who are less inclined to accept side effects and downtime

● It gives the skin a natural glow, a radiant firmness so you can be the best version of you without adding or destroying cells and tissue

25

TREATMENT BENEFITSSkin Rejuvenation

The innovation of the Kleresca® Skin Rejuvenation system lies in its ability to create fluorescent light energy that activates your skin’s collagen-producing cells

The fluorescent light energy penetrates the skin and reaches into multiple layers, boosting collagen production by stimulating the natural processes of the skin

Studies show Kleresca® Skin Rejuvenation induces an approximate 400% increase in collagen production*

Kleresca® Skin Rejuvenation main benefits:● Induces collagen production

● Reduces pore size

● Eliminates fine lines

● Reduces signs of scarring

● Improves overall skin texture

● Induces natural glow

NO DESTRUCTION OF CELLS

NO UV LIGHT

* With LED light as a control, the treatment delivers approximately a 400% increase in collagen production. These results were documented in-vitro and support findings from in vivo studies based on biopsies.

TREATMENT EFFICACYSkin Rejuvenation

With LED light as a control, the treatment delivers approximately a 400% increase in collagen production. These results were documented in-vitro and support findings from in vivo studies based on biopsies.

Baseline 12 weeks

Baseline 12 weeks

Baseline 12 weeks

Increasing collagen

build-up by up to 400%

Reducing fine lines

Reducing pore size

27

KLERESCA® ROSACEA TREATMENTFeel the change

WHAT IS ROSACEA?

PERFECT MARKET FITRosacea

● Kleresca® Rosacea Treatment targets the uncomfortable sensation of stinging and burning skin that rosacea patients typically experience. No other treatments do that

● Suitable even for patients with enhanced skin sensitivity

● Can be used as a stand alone treatment or in addition to traditional therapies

● Being a gentle treatment with no destruction of cells and tissue, it is a welcomed alternative for people who are less inclined to accept side effects and downtime

30

• Reduces inflammation, reducing the presence of papules and pustules

• Reduces erythema and blushing by improving microvascularisation

• Reduces the overall stress level of the skin, thereby reducing the feeling of burning and stinging

• Induces a healing response, improving the overall skin quality

TREATMENT BENEFITSRosacea

31

TREATMENT EFFICACYRosacea

The graphic shows a clear reduction of redness and inflammation in patients suffering with rosacea type II treated with Kleresca® Rosacea Treatment

Baseline 5 weeks after

REDUCTION OF ROSACEA SYMPTOMS

Images: Braun & Gerber. International Journal of Dermatology 2017, 56, 1457-1517. © 2017 The International Society of Dermatology

32

KLERESCA® PRE-POST TREATMENTFor optimal results

IPL/laser treatments

Systemic antibiotics

Benozyl peroxide

Fillers incl. Botox

Skin peelings

Isotretinoin

WHAT IS PRE-POST?

• Kleresca® Pre-Post Treatment does not target one particular therapeutic or aesthetic area

• By stimulating the skin’s own repair mechanisms, the treatment can help prepare and repair the skin in relation to invasive procedures

• The treatment is applicable in combination with a number of commonly used in-clinic treatments for optimised results

34

PERFECT MARKET FITPre-Post

In conjunction with any high-energy and invasive skin treatment, Kleresca® Pre-Post Treatment can optimise results by preparing and repairing the skin through a gentle, non-invasive stimulation of the biological processes.

35

TREATMENT BENEFITSPre-Post

• Reduces inflammation and erythema

• Normalises and de-stresses the skin

• Activates skin cells and induces regenerative processes

• Increases collagen build-up

36

Thank you

ContactMikkel SchoedtGeneral ManagerFB Dermatology LimitedMSC@FB-Dermatology.comwww.FB-Dermatology.com / www.kleresca.com Find us at Cision News, Instagram and LinkedIn